Please login to the form below
Amarin
This page shows the latest Amarin news and features for those working in and with pharma, biotech and healthcare.
NICE recommends Vazkepa for patients at risk of stroke and heart attacks in England and Wales
Amarin’s Vazkepa (icosapent ethyl) has been recommended by the National Institute for Health and Care Excellence (NICE) for adults receiving statin treatment who are deemed to be at high cardiovascular ... Amarin’s senior vice president and president
Latest news
-
Lexicon Pharma announces strong CV data for first-in-class sotagliflozin at the European Society of Cardiology’s annual meeting
Last month Lexicon announced revenues for the three months to 30 June of $9.2m and the appointment of a new chief medical officer, Craig Granowitz, previously CMO at Amarin and
-
CHMP recommends EU approval for Amarin’s cardiovascular risk reduction drug
Amarin was hit again in September 2020, after the US Court of Appeals upheld the lower court’s ruling that invalidated the patents covering Vascepa. ... In a statement, Amarin said that it would be ‘reviewing its legal options’ following the US
-
Amarin shares tumble following Vascepa patent loss
is approved by FDA, prevent launch of generic versions of Vascepa,” said John Thero, CEO of Amarin. ... The patent ruling only applies to Vascepa’s US patent exclusivity, with Amarin clarifying that its patents elsewhere in the world still stand.
-
Northsea Therapeutics raises $40m to develop fish oil NASH drug
The outlook for Northsea looks positive given Amarin’s success with its own fish oil-derived drug Vascepa (icosapent ethyl). ... This blockbuster indication has Amarin “aggressively launching” Vascepa in the US, after the company estimated expected
-
FDA okays Amarin’s Vascepa for cardiovascular risk reduction
Drug is on course for blockbuster sales. Amarin has been given an early Christmas present by the FDA – the approval of its fish oil-derived drug Vascepa to reduce the risk ... The expanded approval for Amarin’s only marketed product was odds on after
More from news
Approximately 12 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Medius Deal Watch table for February 2015
aureus and Shigellosis. Corporate acquisition. 190. Amarin/ Eddingpharm. VASCEPA (icosapent ethyl) - triglyceride level reduction.
-
Pharma deals during November 2012
All may not be plain sailing with this BASF strategy however given the promise of a crowded market place with the anticipated introduction of Amarin's Vascepa next year, to be
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Teva's Mark Salyer joins Amarin
Takes up newly-created chief commercial officer role. Amarin has appointed Mark Salyer to the newly-created position of chief commercial officer. ... Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- Sanofi halts recruitment for trials assessing MS treatment
- BeiGene announces positive phase 3 trial results for liver cancer treatment
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- A creative awakening – how pharma is bringing innovation to the patient journey
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
PMHub
Apex.co.uk Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
